LIXTE Biotechnology Holdings (NASDAQ: LIXT) is expanding its presence across multiple segments of oncology innovation in 2025, driven by its clinical-stage pipeline centered on LB-100, a first-in-class inhibitor of protein phosphatase 2A (PP2A). According to a recent article, LB-100 is designed to enhance the effectiveness of established cancer therapies rather than replace them. By inhibiting PP2A, the compound stimulates cell-cycle progression and interferes with DNA repair in cancer cells, potentially making tumors more responsive to chemotherapy and immunotherapy.
LB-100 is currently being evaluated in multiple clinical programs targeting solid tumors with significant unmet medical need, including ovarian clear cell carcinoma, metastatic colon cancer, and advanced soft tissue sarcoma. The company has demonstrated that LB-100 is well-tolerated in cancer patients at doses associated with anti-cancer activity, based on extensive published preclinical data available at www.lixte.com. This compound is part of a pioneering effort in an entirely new field of cancer biology known as activation lethality, which is advancing a new treatment paradigm.
LIXTE's approach is covered by a comprehensive patent portfolio. Proof-of-concept clinical trials are currently in progress for ovarian clear cell carcinoma and metastatic colon cancer. The company's focus on PP2A inhibition represents a novel strategy in the cancer treatment landscape, aiming to improve outcomes for patients by making existing therapies more effective.
For more information on LIXTE Biotechnology Holdings and its pipeline, visit the company's newsroom at https://ibn.fm/LIXT. The full article discussing LB-100's potential can be accessed at https://ibn.fm/iCydh.
